Brenntag Specialties Acquires mcePharma to Enhance Biopharmaceutical Capabilities in EMEA
Brenntag, a global leader in chemical and ingredient distribution, has announced the acquisition of mcePharma a.s., a Czech-based company specializing in pharmaceutical and biopharmaceutical services. This strategic move aims to bolster capabilities across the pharmaceutical and biopharmaceutical value chain, particularly in the Europe, Middle East, and Africa (EMEA) region.
Expanding GMP Value-Added Services
The acquisition of mcePharma brings state-of-the-art Good Manufacturing Practice (GMP) facilities, advanced sampling services, and expertise in over-the-counter (OTC) product development and GMP powder packaging to Brenntag’s portfolio. These additions are expected to enhance offerings to both principals and customers in the EMEA region.
Joakim Rehné, President Pharma EMEA at, stated, “The integration of GMP blending and down-packing, along with added warehouse and office space, positions us to meet growing demand while ensuring operational excellence. It’s a powerful enhancement to our portfolio that reinforces our commitment to quality, speed, and customer-centric solutions.”
Strategic Location and Infrastructure
mcePharma’s location in the Czech Republic offers a strategic advantage for, providing a central hub for GMP value-added services. The existing infrastructure includes advanced facilities for blending, packaging, and warehousing, which are essential for meeting the increasing demands of the biopharmaceutical market.marketscreener.com
Ivan Mikes, Member of the Administration Board of mcePharma, commented, “After growing our portfolio and expertise in development, production, and warehousing for distribution of specialty chemicals and services, we are excited to expand our reach and customer base significantly by joining Brenntag. Our team will get the chance to leverage their expertise and serve the entire EMEA region together with the Brenntag Pharma colleagues.”
Enhancing Biopharmaceutical Services
The acquisition aligns with Brenntag’s strategic initiatives to expand its biopharmaceutical services beyond traditional small molecules. By incorporating mcePharma’s capabilities, Brenntag aims to serve additional customers with value-added services and meet the needs of supply partners in the rapidly growing biopharmaceutical market in EMEA and globally.
Gust Desmedt, Global President Pharma at Brenntag Specialties, noted, “This acquisition represents a key milestone in our strategic initiatives to further expand our biopharmaceutical services on top of our offering in traditional small molecules. With the added capabilities mcePharma offers, we are confident we can serve additional customers with value-added services and serve the needs of our supply partners in the rapid growing Biopharma market in EMEA and globally with specialized biobuffers.”
Future Investments and Developments
Brenntag plans to make additional investments in the mcePharma site to further expand its capabilities. These investments will focus on integrating GMP biobuffers and liquid blending services to meet the increasing demand from customers and supply partners. The goal is to create a unique position in the biopharmaceutical market by offering comprehensive GMP value-added services.
The acquisition of mcePharma by Brenntag Specialties marks a significant step in enhancing Brenntag’s pharmaceutical and biopharmaceutical capabilities in the EMEA region. With the integration of mcePharma’s advanced facilities and expertise, Brenntag is poised to meet the growing demand for GMP value-added services in the biopharmaceutical market, reinforcing its commitment to quality, speed, and customer-centric solutions.
